HIGHLIGHTS
- who: JNCI Cancer Spectrum ( and collaborators from the DivisionAdministration, Silver Spring, MD, USA have published the paper: Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety, in the Journal: (JOURNAL) of March/17,/2022
- what: This research emulates a randomized comparative safety study, the PRONOUNCE trial , which was designed to evaluate the comparative risk of major adverse cardiovascular events (MACE), defined as a composite of allcause mortality, nonfatal myocardial infarction, or nonfatal stroke, among advanced prostate cancer patients treated with androgen_deprivation_therapy. The trial was intended to address conflicting reports . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.